PCSK9 Patent Battle: Amgen Seeks Supreme Court Review Ahead Of February Trial

Amgen opposes US Federal Circuit's standard for determining adequacy of an invention's written description, which led court to overturn jury verdict that its Repatha patents are valid.

Supreme Court long shot

In a new twist in the ongoing PCSK9 patent saga, Amgen Inc. has asked the US Supreme Court to step in and answer a question that could determine the outcome of its litigation with Sanofi/Regeneron Pharmaceuticals Inc.

The companies are set to square off in a second jury trial over the validity of two Amgen patents, scheduled...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Legal & IP

More from Pink Sheet